EN DE
Watch Nath Bio-Genes (India) Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nath Bio-Genes (India) Limited (NATHBIOGEN) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Nath Bio-Genes (India) Limited stock ₹270, price ₹136, upside +98.1%, quality 44 out of 100. Rating: strongly undervalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE448G01010

NB Nath Bio-Genes (India) Limited logo Some data Nov 12, 2026

Nath Bio-Genes (India) Limited

NATHBIOGEN · NSE

Cheap (50% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹269.85 · Strongly undervalued 
Low debt 
Ranks above peers (11/13) 
Even on cautious assumptions the value is 55% above the price (₹211.76). 
Quality 44/100 
Expensive Growth (revenue 5y +7.7 %/yr in INR) 
Thin margins · 9.3% net margin (TTM) 
1.5% dividend yield · Watch coverage
Some data 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 43/100
⟳ Cyclical
Watch Nath Bio-Genes (India) Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹358.65 ₹127.33 Fair Value ₹269.85 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range ₹127.33 – ₹358.65 · fair‑value band ₹211.76 – ₹372.69 · the ₹136.19 price screens below the ₹269.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Nath Bio-Genes (India) in your weekly email

Every Wednesday you see whether Nath Bio-Genes (India) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities.

Show moreShow less

The company offers fiber and oil seeds, including cotton and mustard; plant nutrient supplements; pearl millets; seeds for field crops, such as bajra, maize, corn, paddy, wheat, and jowar; and seeds for vegetables comprising chilli, okra, tomato, bitter gourd, and cucumber.

It also provides crop protection supplements under the Win-chi-Win, WinGoli, and WinPro Granules brands; and forage seeds under the NUTRIMAX GOLD and NUTRIMAX brand names. The company was founded in 1979 and is based in Mumbai, India.

Stock analysis

Nath Bio-Genes (India) Limited (NATHBIOGEN) currently trades at ₹136.19, while our model-based Fair Value estimate is ₹269.85, implying the stock looks roughly 50% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹347.35 per share, and 15 of the 17 models we run sit above the ₹136.19 price.

Bear case: the Asset-Based group reads lowest at ₹190.43, and 2 of the 17 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹211.76 (bear) to ₹372.69 (bull), the price of ₹136.19 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Nath Bio-Genes (India) Limited reported revenue of ₹4.5B in FY2026 versus ₹2.8B in FY2022, a compound +12.5%/yr. Reported net income was ₹416M in FY2026.

Key figures

Market cap ₹2.7B (≈ $28.7M) Micro · P/E ratio 7.4 · P/S ratio 0.55 · EPS (TTM) ₹18.43 · Dividend yield 1.5% · Net margin 9.3% · Return on equity 6.3% · Return on assets (EBIT) 10.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at 17% fair-value upside, at 98%, NATHBIOGEN screens cheaper than that median.

Fair Value models

Bear ₹211.76 Fair Value ₹269.85 Bull ₹372.69
Price ₹136.19 · Upside +98.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹10.35 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹202.32 ₹299.39 ₹437.59 76
Residual Income ₹258.27 ₹254.44 ₹268.45 76
EPV ₹202.60 ₹224.30 ₹242.10 74
All 17 models by family
DCF Models
Owner Earnings ₹202.32 ₹299.39 ₹437.59 76
Earnings-Based
Graham-Dodd ₹148.96 ₹635.30 ₹867.67 64
Lynch FV ₹174.54 ₹249.34 ₹324.14 61
PEG = 1.0 ₹174.54 ₹249.34 ₹324.14 57
EPV ₹202.60 ₹224.30 ₹242.10 74
Dividend Discount
Gordon GGM ₹14.57 ₹25.09 ₹33.29 68
DDM Multi-Stage ₹14.57 ₹23.47 ₹26.93 67
Multiples
P/E Multiple ₹279.30 ₹372.40 ₹465.50 63
P/S Multiple ₹263.49 ₹351.32 ₹439.15 58
P/B Multiple ₹173.21 ₹230.95 ₹288.69 55
EV/EBIT ₹234.94 ₹324.21 ₹413.49 66
EV/EBITDA ₹174.06 ₹243.04 ₹312.03 67
EV/Revenue ₹199.23 ₹298.71 ₹398.19 53
Asset-Based
NCAV (Graham) ₹125.69 ₹190.43 ₹238.04 54
Economic Profit
Residual Income ₹258.27 ₹254.44 ₹268.45 76
ROIC Compounder ₹202.60 ₹224.30 ₹242.10 72
Growth Earnings
Growth-Adj P/E ₹243.15 ₹347.35 ₹451.56 67

The fair value above starts from this blend and is adjusted for a cyclical peak year.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 57
Debt, balance sheet and risk of trouble
Investment 71
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 57
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Start year 2021 (pandemic). Over 10 years: +10.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.6%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5.6% vs 7.5%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 11%
Pace: the 5-year rate starts in 2021 (pandemic)

Watch NATHBIOGEN, get fair value alerts →

Compare Nath Bio-Genes (India) Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 174 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside +98.1% · Top 25%
Profitability
Return on equity (12 months) 6.3% · Above median
Return on assets 3.8% · Above median
Net margin (12 months) 9.3% · Top 25%
Operating margin (12 months) 10.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 15.8% · Above median
Dividend yield (12 months) 1.5% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Agricultural Inputs median · lower = cheaper

P/E (12 months) 7.4× · Cheapest 25%
P/B 0.40× · Cheapest 25%
P/S (12 months) 0.55× · Cheaper than median
EV/EBITDA 3.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 17
FUTURE (revenue growth)79 · sector 16
PAST (return on equity)25 · sector 25
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)29 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Agricultural Inputs stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nath Bio-Genes (India) Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nath Bio-Genes (India) Limited Fair Value". https://www.fairvalue-calculator.com/stock/NATHBIOGEN

Frequently asked questions

Is Nath Bio-Genes (India) Limited (NATHBIOGEN) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of ₹269.85 versus a price of ₹136.19, about +98% upside (undervalued).
What is the fair value of NATHBIOGEN?
Our model-based fair value for Nath Bio-Genes (India) Limited is ₹269.85 (as of Nov 12, 2026), built from audited fundamentals. The current price: ₹136.19.
What is the quality score of NATHBIOGEN?
Nath Bio-Genes (India) Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Our model-based price target is the fair value of ₹269.85 (as of Nov 12, 2026) from 17 valuation models. Cautious scenario ₹211.76, optimistic scenario ₹372.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Nath Bio-Genes (India) Limited stock forecast for 2026?
Our models put fair value at ₹269.85, about +98% upside versus a price of ₹136.19 (undervalued). Cautious scenario ₹211.76, optimistic scenario ₹372.69. The calculation is refreshed regularly with new filings.
What is the revenue of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Nath Bio-Genes (India) Limited reported trailing-twelve-month revenue of about ₹4.9B (latest available figure, as of Nov 12, 2026).
Does Nath Bio-Genes (India) Limited pay a dividend?
Nath Bio-Genes (India) Limited currently shows a dividend yield of 1.47% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Nath Bio-Genes (India) Limited (NATHBIOGEN) and when is the ex-dividend date?
Nath Bio-Genes (India) Limited pays a dividend of ₹2.00 per share a year, a dividend yield of 1.5%. The last ex-dividend date was Sep 11, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 10.9% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nath Bio-Genes (India) Limited it is ₹269.85 per share (as of Nov 12, 2026), against a price of ₹136.19. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Nath Bio-Genes (India) Limited stock overvalued or undervalued in 2026?
As of Nov 12, 2026, NATHBIOGEN trades below its calculated fair value: price ₹136.19, fair value ₹269.85, a gap of about +98% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NATHBIOGEN?
No. The price is what the market pays today (₹136.19); the fair value is what the company's own numbers justify (₹269.85). For Nath Bio-Genes (India) Limited the two are ₹133.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nath Bio-Genes (India) Limited worth?
The market values Nath Bio-Genes (India) Limited at about ₹2.7B (market capitalisation, as of Nov 12, 2026). Per share that is ₹136.19; our models calculate a fair value of ₹269.85 per share.
What do the bullish and bearish scenarios say about NATHBIOGEN?
Our models span a range for Nath Bio-Genes (India) Limited: cautious scenario ₹211.76, base ₹269.85, optimistic ₹372.69 per share (as of Nov 12, 2026, price ₹136.19). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NATHBIOGEN?
Nath Bio-Genes (India) Limited trades at a price-to-earnings ratio of 7.4 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹269.85 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2026), reported earnings: 8.4. Other multiples: P/B 0.4, P/S 0.6, EV/EBITDA 3.6.
How solid is the balance sheet of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Balance-sheet figures for Nath Bio-Genes (India) Limited (as of Nov 12, 2026): return on equity 6.3%, debt of 0.03 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is NATHBIOGEN from its 52-week high?
Nath Bio-Genes (India) Limited trades at ₹136.19, about 30% below its 52-week high of ₹193.44 and 7% above the low of ₹127.33 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹269.85 is for.
Which stocks are comparable to Nath Bio-Genes (India) Limited?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, SABIC Agri-Nutrients Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nath Bio-Genes (India) Limited stock attractive at the current price?
The data as of Nov 12, 2026: price ₹136.19, calculated fair value ₹269.85 (+98%), Quality Score 44/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NATHBIOGEN calculated?
We run Nath Bio-Genes (India) Limited through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹269.85 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Nath Bio-Genes (India) Limited currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The closing price on Nov 16, 2026 was ₹136.19. Our model-based fair value is ₹269.85, about +98% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nath Bio-Genes (India) Limited right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹211.76). The market is more pessimistic than our downside scenario.
Where does the earnings growth of Nath Bio-Genes (India) Limited (NATHBIOGEN) come from?
Earnings per share at Nath Bio-Genes (India) Limited grew 6.6 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.0 %, EBIT margin +0.1 %, tax rate −0.3 %, residual (interest, one-offs) +0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Nath Bio-Genes (India) Limited

How large is the market capitalisation of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The market capitalisation of Nath Bio-Genes (India) Limited is ₹2.7B (≈ $28.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The price-to-sales ratio of Nath Bio-Genes (India) Limited is 0.55 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Earnings per share at Nath Bio-Genes (India) Limited are ₹18.43 (price ÷ EPS = P/E 7.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The dividend yield of Nath Bio-Genes (India) Limited is 1.5% (payout 10.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The net margin of Nath Bio-Genes (India) Limited is 9.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The return on equity (ROE) of Nath Bio-Genes (India) Limited is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
On an EBIT basis the return on assets of Nath Bio-Genes (India) Limited is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nath Bio-Genes (India) Limited (NATHBIOGEN)?
The operating margin of Nath Bio-Genes (India) Limited is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Revenue at Nath Bio-Genes (India) Limited is growing 15.8% versus a year earlier (3y avg +13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nath Bio-Genes (India) Limited (NATHBIOGEN)?
Earnings per share at Nath Bio-Genes (India) Limited are down 13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nath Bio-Genes (India) Limited (NATHBIOGEN) generate?
The free cash flow of Nath Bio-Genes (India) Limited is −₹250M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nath Bio-Genes (India) Limited (NATHBIOGEN) carry?
The net debt of Nath Bio-Genes (India) Limited is ₹625M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Nath Bio-Genes (India) Limited in the live analysis

One click puts Nath Bio-Genes (India) Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.